
Does low-dose oral minoxidil work for hair loss? What studies show
A blood pressure drug has become one of the hottest topics in hair loss treatment. Here's what the published studies support, and where they fall short.
Low-dose oral minoxidil is used off-label for hair loss, and the research behind it is growing but still uneven. Observational data suggest hair density rises with the dose. A large multicentre safety study found mostly cosmetic side effects and few people stopping. In a 2024 randomised trial, the tablet did not beat the solution on the primary outcome. The same year brought an international consensus with recommended starting doses, contraindications and follow-up.
Why is everyone suddenly talking about minoxidil tablets?
Because dermatologists have gone back to the original blood pressure tablet, in small doses, to make hair grow. Minoxidil arrived in the 1970s for high blood pressure, and its side effect of extra hair growth led to the solution that became the first approved treatment for hereditary hair loss. Low-dose oral minoxidil (LDOM) is used off-label, and no medicines regulator has approved the tablet for hair loss.
Minoxidil was developed in the 1970s as a tablet for severe high blood pressure. It was the side effect that made it famous: patients grew hair where they didn't want it. The manufacturer made a solution to apply to the skin, and it became the world's first approved medicine for hereditary hair loss. For four decades, the topical form was the only minoxidil approved for use on the scalp.
Now dermatologists have gone back to the tablet. The dose is far lower than for high blood pressure, and the point is to make hair grow. This is called low-dose oral minoxidil, often shortened to LDOM, and it is prescribed off-label. Only minoxidil solution and finasteride 1 mg have formal approval for androgenetic alopecia. No regulator has approved minoxidil tablets for hair loss. In Norway, no minoxidil tablet has a standard marketing authorisation. The tablets listed in Felleskatalogen (the Norwegian medicines compendium), such as Loniten and Lonolox, need an exemption from marketing authorisation, so your doctor has to apply for it on your behalf.
Off-label use doesn't mean something is unknown or irresponsible. A lot of everyday medicine works that way. It does mean the evidence base is of a different kind than for approved medicines. It rests on retrospective cohorts, observational series and a handful of clinical trials. The large registration trials that approval requires don't exist. That shapes everything you read below.
This review sticks to what has actually been measured. If you're weighing medication against a procedure, you'll find more options in the guide to non-surgical hair loss treatments.
How low is a low dose?
Below 5 mg a day. Typical levels are 0.5 to 1 mg for women and 2.5 to 5 mg for men, while treating high blood pressure takes several tens of milligrams. As a starting dose, the 2024 consensus recommended 1.25 mg a day for adult women and 2.5 mg for adult men.
Used for high blood pressure, minoxidil is taken at several tens of milligrams a day. For hair loss, the dose is just a small fraction of that. The term LDOM usually covers any dose below 5 mg a day, and most prescriptions sit well under that limit.
| Group | Usual daily dose | Starting dose in the 2024 consensus |
|---|---|---|
| Adult women | 0.5 to 1 mg | 1.25 mg |
| Adult men | 2.5 to 5 mg | 2.5 mg |
Doctors usually start low and adjust according to how well you tolerate the tablet and how your hair responds. The consensus is covered in more detail further down.
Why a tablet when the solution exists?
The reasons are mostly practical. The solution has to go on a dry scalp once or twice every single day. It can leave residue, irritate the skin and ruin your hairstyle. Many people stop using it regularly, and that's a well-known weakness. A tablet removes the application altogether and works evenly across the whole scalp, including patches that are easy to miss or skip.
The counterargument is just as down to earth. A tablet works throughout the body, and the hair growth doesn't stay on your head.
Does a higher dose give more hair?
In the published studies, yes, but side effects rise too. In a 2022 meta-regression of six studies, each extra 1 mg a day gave, after six months, +47.1 hairs/cm² in total, +9.1 hairs/cm² among terminal hairs and +1.4 μm thicker shafts. The analysis was ecological and shows an association, not cause.
The best pooled analysis so far comes from Gupta and colleagues. It is a systematic literature review with meta-regression, published in Skin Appendage Disorders (2022). Six studies with doses between 0.25 mg and 5 mg a day were combined to answer one question: does the effect increase as the dose increases?
The answer was yes. This is how the measures changed after six months for every extra milligram a day:
| Measure | Change | p |
|---|---|---|
| Hairs per cm², all | +47.1 | 0.007 |
| Hairs per cm², terminal | +9.1 | 0.001 |
| Hair shaft diameter | +1.4 μm | 0.013 |
| Hypertrichosis | +17.9 % | 0.006 |
| Cardiovascular side effects | +4.8 % | 0.004 |
The bottom two rows show that side effects rose in the same analysis. Benefit and drawback move together, and that is the very heart of dosing this medicine.
How much weight should the finding carry?
The authors made no secret of the weakness, and it deserves to be up front. The analyses were ecological, meaning they were based on average values for whole groups across studies, not individuals in a randomised comparison. With a design like that, you can see an association but you can't prove cause. The authors themselves say randomised trials are needed before anyone can speak about cause.
The honest reading is therefore that the studies we have show better measurements at the higher doses. The pattern is stable enough to serve as a guide when a doctor sets the dose. What it can't tell you for certain is whether you personally will get more hair by going up a dose.
Does the tablet work better than the solution?
That couldn't be shown. In a randomised trial published in 2024 with 90 men, minoxidil 5 mg as a tablet did not give significantly denser terminal hair than minoxidil 5 % solution after 24 weeks. The groups differed by 3.1 hairs/cm² at the front and 23.4 hairs/cm² at the crown. Of those on the tablet, 49 % got hypertrichosis, against 25 % on the solution, while more people in the solution group stopped because of side effects.
The natural next question: is the tablet better than the solution? The clearest answer we have came in 2024 from Penha and colleagues in JAMA Dermatology. The trial was double-blind, placebo-controlled and randomised. Men with androgenetic alopecia either took 5 mg minoxidil as a tablet every morning or applied 5 % solution morning and evening.
90 men were randomised, 45 to each group, and 68 completed all 24 weeks. The primary outcome was the density of terminal hairs.
What the trial found
The tablet did not come out demonstrably better. None of the differences in terminal hair were statistically significant.
| Measure | Area | Difference | Confidence interval | p-value |
|---|---|---|---|---|
| Terminal hairs (primary outcome) | Front | 3.1 hairs/cm² | 0.27 | |
| Terminal hairs (primary outcome) | Crown | 23.4 hairs/cm² | 0.09 | |
| Photo assessment (secondary) | Crown | 24 % | 0 to 48 (95 %) | 0.04 |
| Photo assessment (secondary) | Front | 12 % | −12 to 36 (95 %) | 0.24 |
Only the photo assessment at the crown came out in the tablet's favour. When the lower limit of the confidence interval sits at zero, the result is weak. It also came from a secondary endpoint. Read it as a hint, not a finding.
Side effects in each group
| Complaint | Tablet | Solution |
|---|---|---|
| Hypertrichosis | 49 % | 25 % |
| Headache | 14 % | |
| Scalp eczema | 16 % | |
| Itching | 11 % |
So the solution group got the typical complaints of a topical treatment. Three in the solution group and one in the tablet group stopped because of side effects.
What the trial means in practice is not that the tablet doesn't work. At those doses and over 24 weeks, the tablet ended up roughly level with a non-prescription product, and it acts throughout the body. If the solution gives you a rash or you keep forgetting it, this finding points towards the tablet.
What does the largest safety study show?
That side effects are mostly cosmetic. In a retrospective review published in 2021, 1,404 patients had used LDOM for three months or more, and 15.1 % of them got hypertrichosis. Dizziness, fluid retention and palpitations were each under 2 %, and only 1.7 % stopped because of side effects.
The largest body of safety data is a retrospective multicentre study led by Vañó-Galván (Journal of the American Academy of Dermatology, 2021). It included 1,404 patients who had used LDOM for at least three months, for all types of alopecia.
| Women | 943 (67.2 %) |
|---|---|
| Men | 461 (32.8 %) |
| Average age | 43 years |
| Youngest and oldest | 8 and 86 years |
What was recorded
- Hypertrichosis, 15.1 %. By far the most common side effect, and the one most often underestimated. It led 14 patients (0.5 %) to stop.
- Dizziness, 1.7 %
- Fluid retention, 1.3 %
- Palpitations, 0.9 %
- Headache, 0.4 %
- Swollen eyelids, 0.3 %
- Sleep problems, 0.2 %
Systemic side effects, meaning complaints beyond the skin, led 29 patients (1.2 %) to stop. Both percentages are based on 2,469 treatment courses rather than the 1,404 patients, because a patient whose dose was changed was counted once per dose. In total, only 1.7 % stopped because of a side effect.
How to read the numbers
The figures are reassuring, and they explain why more and more people are given the tablet. But two caveats belong with them. The study was retrospective. It recorded what was in the medical notes, not answers to questions every patient was asked, and mild complaints are almost certainly under-reported. Hypertrichosis is called a minor cosmetic side effect in medical language. For you, it can mean visible hair growth on your face, back or arms. When roughly one patient in seven gets it, it belongs in the conversation before you swallow the first tablet.
What does the 2024 international consensus recommend for starting LDOM?
In November 2024, JAMA Dermatology published a Delphi consensus in which 43 dermatologists from 12 countries agreed on 76 points. The panel recommended 1.25 mg a day as a starting dose for women and 2.5 mg for men, listed heart failure and pregnancy among the contraindications, and said you have to wait three to six months before anything shows.
In November 2024, JAMA Dermatology published a consensus, drawn up with a modified Delphi method and an international panel, on how to start LDOM. 43 dermatologists from twelve countries agreed on 76 points. They cover diagnosis, indication, dosing, contraindications, checks before starting, follow-up and when a patient should be referred on. When a medicine is used off-label, this is the closest thing to a shared standard you'll find today.
Starting dose
| Age | Women and girls | Men and boys |
|---|---|---|
| 18 and over | 1.25 mg a day | 2.5 mg a day |
| 12 to 17 | 0.625 mg a day | 1.25 mg a day |
When the tablet should not be used
The list included hypersensitivity to minoxidil, serious interactions with other medicines, previous fluid around the heart or tamponade, pericarditis and heart failure. Pulmonary hypertension associated with mitral stenosis and phaeochromocytoma were also on it, along with pregnancy and breastfeeding.
When extra caution is needed
A history of palpitations or heart rhythm disorders, low blood pressure, reduced kidney function and dialysis were counted as conditions where the doctor must be careful. They are not absolute barriers. The doctor has to make an assessment, but treatment isn't automatically ruled out.
How long it takes
The panel expected LDOM to show an effect after three to six months at the earliest. That affects what you should expect. If you give up after six weeks because the mirror shows nothing, you've stopped too soon.
A consensus is agreement between experts, not the result of trials. It brings together the judgement of doctors who prescribe the medicine often. Where the studies are thin, that is valuable, but a randomised comparison counts for more.
How does the tablet fit with a hair transplant?
The two complement each other. A transplant moves hair you have, while minoxidil works on the hair that's still there. Many people use both, because surgery doesn't slow the hereditary loss elsewhere on the head. Tell your surgeon you take minoxidil, which widens the blood vessels, and if you start just before the procedure, the shedding afterwards becomes hard to interpret.
Medication and surgery solve two different problems. A transplant moves the hair you have left to areas that are bald. The medicine works on the hair that's still there, trying to slow or partly reverse miniaturisation. One doesn't replace the other, and it's in the interplay between them that things most often go wrong.
Why your original hair still matters
Surgery doesn't stop the hereditary hair loss around the transplanted area. If your own hair keeps thinning behind a new hairline, the overall look can fall out of balance within a few years, even while the transplanted hairs do their job perfectly. That's why continuing medical treatment after surgery is often recommended, and that applies equally to the tablet and the solution.
Speak up, and think about timing
Two things are worth keeping in mind. Every hair loss medicine should go on the consultation form, along with everything else you take. Minoxidil widens the blood vessels, so it's information the surgeon needs. And if you start LDOM right before the procedure, the early shedding minoxidil sometimes causes can overlap with the shock loss that follows surgery. Then it's hard to know which is which. What counts as normal shedding after a procedure is covered in the aftercare guide.
Not sure whether surgery is right for you at all? Go through the criteria in the guide to who is suited to the procedure. If you're a woman, start with the guide for women losing hair, as both the assessment and the choice of medicine differ from men's.
What don't we know about LDOM yet?
Quite a lot. No one has documented cardiovascular safety beyond a few months. The best dose is unknown, because side effects rise along with the effect. No study has shown the tablet beats the solution, combining it with finasteride or a transplant hasn't been studied, and what happens after you stop is poorly described.
The gaps in knowledge are large, and an honest review has to include them.
- We know little about long-term safety. The largest body of safety data is retrospective and covers use for three months or more. Ten years of prospective cardiovascular follow-up in healthy people taking the tablet for cosmetic reasons has not been published.
- No one knows the best dose. The effect seems to increase with the dose, but the same analysis shows side effects increase just as much. Where the balance point lies for each person, no study has settled.
- The tablet hasn't beaten the solution. There is only one randomised trial comparing them head to head, and it found no advantage.
- Combinations are little studied. In practice, most people use more than one treatment. The interplay between LDOM and finasteride, or between LDOM and a procedure, hasn't been measured under controlled conditions.
- What happens after stopping is unclear. As with the solution, the effect is assumed to require you to keep going, but the course after stopping LDOM specifically is poorly mapped.
This isn't an argument against the tablet. It's an argument for using it as prescription treatment, followed up by a doctor who has an overview of your heart health, and not as something you order online like a dietary supplement.
What do people most often ask about LDOM?
LDOM is not approved for hair loss and is prescribed off-label. According to the 2024 consensus, the effect shows after three to six months at the earliest. Extra body hair, hypertrichosis, affects 15.1 % and goes away when you stop. If you have heart or kidney problems, you need to be assessed first. Women can use it, including before the menopause, whereas finasteride lacks approval for women and is ruled out for anyone who could become pregnant. Where the hair is already gone, the tablet can't do the job of a transplant.
Is the tablet approved for hair loss?
No, it's used off-label. Approval covers only the solution and finasteride 1 mg a day for androgenetic alopecia. Prescribing medicines off-label is legal and common, but you and your doctor take on more responsibility.
When can I expect results?
The 2024 international consensus says three to six months at the earliest. Hair grows slowly in cycles, and no treatment shows results before the follicle has had time to produce new hair.
Will I get more hair elsewhere on my body?
Often a little, yes. In the safety study of 1,404 patients, 15.1 % got hypertrichosis. In the tablet group of the randomised trial, the share was 49 %. The higher the dose, the more hair, and it disappears when you stop. This is the main reason patients want to stop.
Do my blood pressure or heart need monitoring?
Your doctor decides that based on your medical history. The consensus put heart and kidney disease on the lists of contraindications and precautions precisely because such conditions change the assessment. If you have heart disease, low blood pressure or reduced kidney function, your doctor must consider it before you start.
Is LDOM suitable for women?
Yes. 67.2 % of the patients in the largest safety study were women. Women usually get a lower dose than men. This is where the tablet differs from finasteride, which lacks approval for women and is only exceptionally prescribed to them off-label, mostly after the menopause.
Can the tablet replace a transplant?
No, they do different jobs. The tablet works on hair you still have. A procedure moves hair to places where it has disappeared. If hair loss is in its early stages, so the hair is thin but still there, medication alone is often a sensible first step.
Sources
- Gupta AK, et al. There Is a Positive Dose-Dependent Association between Low-Dose Oral minoxidil and Its Efficacy for Androgenetic Alopecia: Findings from a Systematic Review with Meta-Regression Analyses. Skin Appendage Disorders, 2022. pmc.ncbi.nlm.nih.gov/articles/PMC9485924
- Vañó-Galván S, et al. Safety of low-dose oral minoxidil for hair loss: A multicenter study of 1404 patients. Journal of the American Academy of Dermatology, 2021. pubmed.ncbi.nlm.nih.gov/33639244
- Penha MA, Miot HA, Kasprzak M, Müller Ramos P. Oral minoxidil vs Topical minoxidil for Male Androgenetic Alopecia: A Randomized Clinical Trial. JAMA Dermatology, 2024. pmc.ncbi.nlm.nih.gov/articles/PMC11007651
- Akiska YM, Mirmirani P, Roseborough I, Mathes E. Low-Dose Oral minoxidil Initiation for Patients With Hair Loss: An International Modified Delphi Consensus Statement. JAMA Dermatology, 2025;161(1):87-95. pubmed.ncbi.nlm.nih.gov/39565602
This article summarises published research and is meant as general information. It is not medical advice, nor advice to start or stop any medicine. Minoxidil tablets require a prescription and have cardiovascular contraindications. Talk it over with your doctor, who knows your medical history.
Wondering what's possible for your hair?
Send three sharp photos of your hair, from the front, the top and the back. You'll get an honest answer on what can be done, roughly how many grafts it would take and what it costs.
- Free and with no obligation
- Photos are assessed by the clinic's medical team
- Replies usually within an hour in the daytime
A study tells you something about groups. Only a doctor who has seen your photos can say what applies to your hair. The medical team at the clinic at the top of our ranking offers a free assessment.
Goes to the clinic at the top of our ranking.

